GlassScriptPhysician profile
Cheryl Duncan
NPI 1891712774
$1,795.17
in general payments reported to CMS, 2019-2025
33 companies · $111 in 2025
The $111 reported for 2025 was less than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $264 · 2023: $856 · 2024: $564 · 2025: $111.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,488 · Education: $43.25.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,488.28 |
| Education | $43.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $205.11 | 2022-2024 | Imbruvica, Tecvayli, Darzalex |
| Novartis Pharmaceuticals Corporation | $203.07 | 2022-2024 | |
| Astrazeneca Pharmaceuticals LP | $137.13 | 2022-2025 | Enhertu, Calquence, Imfinzi |
| Celgene Corporation | $125.06 | 2022-2024 | Reblozyl, Pomalyst |
| Beigene USA, INC. | $114.95 | 2023-2024 | Brukinsa |
| Merck Sharp & Dohme LLC | $86.71 | 2023-2024 | Keytruda, Lenvima, Welireg |
| Genentech USA, INC. | $86.41 | 2022-2024 | Polivy, Tecentriq, Phesgo |
| Abbvie INC. | $85.10 | 2024-2025 | |
| Genzyme Corporation | $73.55 | 2022-2024 | |
| Daiichi Sankyo INC. | $69.63 | 2023-2024 | Enhertu |
| Takeda Pharmaceuticals U.S.A., INC. | $59.13 | 2023-2024 | Alunbrig, Ninlaro |
| Pfizer INC. | $57.91 | 2023-2024 | |
| Incyte Corporation | $55.81 | 2023-2024 | Monjuvi |
| Pharmacyclics LLC, An Abbvie Company | $44.02 | 2023 | Epkinly |
| Adaptive Biotechnologies Corporation | $42.24 | 2023-2024 | Clonoseq |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Jazz Pharmaceuticals INC. | $26.72 | 2023 | |
| Regeneron Healthcare Solutions, INC. | $22.50 | 2024 | Libtayo |
| Exelixis INC. | $22.07 | 2023 | Cabometyx |
| Sobi, INC | $21.74 | 2022 | |
| Sun Pharmaceutical Industries INC. | $21.70 | 2023 | Yonsa, Odomzo |
| Boston Scientific Corporation | $21.63 | 2023 | Rhythmia Mapping System |
| Mylan Institutional INC. | $21.31 | 2023 | Ogivri, Fulphila |
| Pharmacosmos Therapeutics INC. | $21.08 | 2024 | Monoferric |
| Mirati Therapeutics, INC. | $19.76 | 2023 | Krazati |
| Eisai INC. | $19.66 | 2023 | |
| Adc Therapeutics America, INC. | $19.03 | 2023 | |
| Servier Pharmaceuticals LLC | $17.98 | 2024 | |
| Myriad Genetic Laboratories, INC. | $17.67 | 2023 | Precisetumor |
| E.R. Squibb & Sons, L.L.C. | $17.00 | 2024 | Opdivo |
| Ipsen Biopharmaceuticals, INC | $15.99 | 2024 | Onivyde, Somatuline Depot |
| Puma Biotechnology, INC. | $15.25 | 2023 | |
| Janssen Pharmaceuticals, INC | $14.22 | 2024 | Xarelto |
| Glaxosmithkline, LLC. | $14.03 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cheryl Duncan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.